BioSyent Announces Health Canada Approval of Thyconvi™ (levothyroxine oral solution)
MISSISSAUGA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that Health Canada has approved Thyconvi™ (levothyroxine sodium), the first and only levothyroxine oral solution available in Canada for the management of hypothyroidism and thyroid-stimulating hormone (“TSH”) suppression. BioSyent Pharma Inc., a subsidiary of the Company, has an exclusive […]
Original Source
Read the full article at Financialpost →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.